AndreaBozzo/ceres-open-data-index huggingface dataset:
Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival

Background
          The patient characteristics and mortality associated with autosomal dominant polycystic kidney disease (PKD) have not been characterized for a national sample of end stage renal disease (ESRD) patients on the renal transplant waiting list.
        
        
          Methods
          40,493 patients in the United States Renal Data System who were initiated on ESRD therapy between 1 April 1995 and 29 June 1999 and later enrolled on the renal transplant waiting list were analyzed in an historical cohort study of the relationship between hematocrit at the time of presentation to ESRD and survival (using Cox Regression) in patients with PKD as a cause of ESRD.
        
        
          Results
          Hematocrit levels at presentation to ESRD increased significantly over more recent years of the study. Hematocrit rose in parallel in patients with and without PKD, but patients with PKD had consistently higher hemoglobin. PKD was independently associated with higher hematocrit in multiple linear regression analysis (p < 0.0001). In logistic regression, higher hematocrit was independently associated with PKD. In Cox Regression analysis, PKD was associated with statistically significant improved survival both in comparison with diabetic (hazard ratio, 0.64, 95% CI 0.53–0.77, p < 0.001) and non-diabetic (HR 0.68, 95% CI 0.56–0.82, p = 0.001) ESRD patients, adjusted for all other factors.
        
        
          Conclusions
          Hematocrit at presentation to ESRD was significantly higher in patients with PKD compared with patients with other causes of ESRD. The survival advantage of PKD in ESRD persisted even adjusted for differences in hematocrit and in comparison with patients on the renal transplant waiting list.
Patent AT-E400200-T1: [Translated] BREATHABLE AND WATERPROOF SHOE SOLE AND METHOD FOR PRODUCING THE SAME

Chemical patent from PubChem database. Patent Number: AT-E400200-T1. Title: Method of Treatment Using Chemical Compounds. Filing Date: 1991-02-16. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: Methods for treating diseases using specific chemical compounds are provided, including dosing regimens and combination therapies for enhanced therape... IPC Classifications: C07D, C07F, A61K. This patent covers 34 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 530414: Trimethylsilyl [hexanoyl(trimethylsilyl)amino]acetate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-[hexanoyl(trimethylsilyl)amino]acetate. Molecular Formula: C14H31NO3Si2. Molecular Weight: 317.57. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Priority setting for new technologies in medicine: A transdisciplinary study

Background
          Decision makers in health care organizations struggle with how to set priorities for new technologies in medicine. Traditional approaches to priority setting for new technologies in medicine are insufficient and there is no widely accepted model that can guide decision makers.
        
        
          Discussion
          Daniels and Sabin have developed an ethically based account about how priority setting decisions should be made. We have developed an empirically based account of how priority setting decisions are made. In this paper, we integrate these two accounts into a transdisciplinary model of priority setting for new technologies in medicine that is both ethically and empirically based.
        
        
          Summary
          We have developed a transdisciplinary model of priority setting that provides guidance to decision makers that they can operationalize to help address priority setting problems in their institution.
Compound 528654: 2-Phenylbutyric acid, TMS derivative

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-phenylbutanoate. Molecular Formula: C13H20O2Si. Molecular Weight: 236.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527719: Isopropyl 2,3-dibromopropanoate

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 2,3-dibromopropanoate. Molecular Formula: C6H10Br2O2. Molecular Weight: 273.95. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400532-T1: [Translated] WATER TREATMENT SYSTEM FOR AND METHOD FOR TREATING WASTEWATER FROM BREEDING FACILITIES FOR AQUATIC ANIMALS

The system performs denitrification on the water obtained from drainage of a pond (60) where water plants (50) are grown. The drainage is arranged at the root area of the water plants. A water supply is provided in the pond. The drainage removes the water from the pond for denitrification. A pump is used for collecting water from the pond.
Compound 526330: 2,4,6,8-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 2,4,6,8-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Cost Report Audited Data Print Image: 2012

This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm.
Compound 528026: 1-Phenylethyl 2-chlorobenzoate

Chemical compound data from PubChem database. IUPAC Name: 1-phenylethyl 2-chlorobenzoate. Molecular Formula: C15H13ClO2. Molecular Weight: 260.71. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - Table 1H. Cholera to Coccidioidomycosis

NNDSS - Table 1H. Cholera to Coccidioidomycosis - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats

Introduction
          Hemofiltration may modulate the inflammatory response in sepsis through a variety of mechanisms. We sought to distinguish clearance from adsorption as the principal mechanism responsible for reducing circulating IL-6 levels with hemofiltration.
        
        
          Materials and methods
          Nine hours after cecal ligation and puncture in 18 adult male Sprague–Dawley rats, we divided the rats into three groups (6 animals each) and placed groups 2 and 3 on a hemofiltration circuit connected between the right carotid artery and femoral vein using an AN69 membrane. In the hemofiltration group (group 2), ultrafiltrate was replaced with lactated Ringer's solution; in the recirculation group (group 3), the ultrafiltrate was reinfused into the animal. A sham group (group 1) had an arteriovenous circuit inserted but no hemofiltration. Blood was obtained for measurement of IL-6 and tumor necrosis factor (TNF) at the start of hemofiltration and after 5 and 11 hours of treatment.
        
        
          Results and discussion
          IL-6 levels increased only in the sham-treated animals (20.4 ± 11.3 at baseline to 62.3 ± 16.8 pg/ml at 11 hours, P = 0.03) (differences between groups 1 and 2, P = 0.015, and groups 1 and 3, P = 0.028). TNF levels were highly variable but not significantly different among the three groups.
        
        
          Conclusion
          Hemofiltration-associated reductions in circulating IL-6 levels appear to be secondary to adsorption of mediators to the filter membrane. We do not know whether this is due to direct adsorption of IL-6 per se or to the absorption of other mediators with secondary downregulation of IL-6 production or release. In addition, we could not exclude an interaction between adsorption and hemofiltration.
Compound 526222: 1,2,3,4,7,9-Hexabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,4,7,9-hexabromodibenzofuran. Molecular Formula: C12H2Br6O. Molecular Weight: 641.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Simpson's paradox and calculation of number needed to treat from meta-analysis

Background
          Calculation of numbers needed to treat (NNT) is more complex from meta-analysis than from single trials. Treating the data as if it all came from one trial may lead to misleading results when the trial arms are imbalanced.
        
        
          Discussion
          An example is shown from a published Cochrane review in which the benefit of nursing intervention for smoking cessation is shown by formal meta-analysis of the individual trial results. However if these patients were added together as if they all came from one trial the direction of the effect appears to be reversed (due to Simpson's paradox).
          Whilst NNT from meta-analysis can be calculated from pooled Risk Differences, this is unlikely to be a stable method unless the event rates in the control groups are very similar. Since in practice event rates vary considerably, the use a relative measure, such as Odds Ratio or Relative Risk is advocated. These can be applied to different levels of baseline risk to generate a risk specific NNT for the treatment.
        
        
          Summary
          The method used to calculate NNT from meta-analysis should be clearly stated, and adding the patients from separate trials as if they all came from one trial should be avoided.
Compound 530022: Isovanilline, MO TMS

Chemical compound data from PubChem database. IUPAC Name: N-methoxy-1-(4-methoxy-3-trimethylsilyloxyphenyl)methanimine. Molecular Formula: C12H19NO3Si. Molecular Weight: 253.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The role of statins as potential targets for bone formation

Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme have recently been shown to stimulate bone formation in rodents both in vitro and in vivo. In bone cells, these inhibitors increase the gene expression of bone morphogenetic protein-2, which is an autocrine-paracrine factor for osteoblast differentiation.
        The findings that statins increase bone formation and bone mass in rodents suggest a potential new action for these compounds, which may be beneficial in patients with established osteoporosis where marked bone loss has occurred. Recent clinical data suggest that they may reduce the risk of fracture in patients taking these drugs.
NCHS - Births to Unmarried Women by Age Group: United States

This dataset includes number of births to unmarried women by age group in the United States since 1940. 

Methods for collecting information on marital status changed over the reporting period and have been documented in:

• Ventura SJ, Bachrach CA. Nonmarital childbearing in the United States, 1940–99. National vital statistics reports; vol 48 no 16. Hyattsville, Maryland: National Center for Health Statistics. 2000. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr48/nvs48_16.pdf.
• National Center for Health Statistics. User guide to the 2013 natality public use file. Hyattsville, Maryland: National Center for Health Statistics. 2014. Available from: http://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm.
Compound 527688: Butanoic acid, 3-chloro, 1-methylethyl ester

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 3-chlorobutanoate. Molecular Formula: C7H13ClO2. Molecular Weight: 164.63. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40181-T1: [Translated] CLAMP CONNECTION.

A clamp (1,13) for joining together overlapping sections of elongate members (3) in, for example, telescopic steel arches used in the mining industry comprises a frontal plate (1) and a U-bolt (13), the arms (9) of the U-bolt being inclined to a line drawn normal to a load bearing surface of the frontal plate (1) at a preferred angle of between 5 DEG  and 40 DEG .
Liothyronine sodium

Liothyronine Sodium is a prescription medication that provides a synthetic form of the thyroid hormone T3, used to treat hypothyroidism (underactive thyroid) by helping regulate metabolism, energy, and body temperature. It comes as oral tablets in strengths of 0.005 mg, 0.025 mg, and 0.05 mg, manufactured by Biocon Pharma Inc. as a generic equivalent. This information was generated using AI and is provided for informational and research purposes only.
Cinacalcet

Cinacalcet Hydrochloride is a prescription medication available as oral tablets in 30mg, 60mg, and 90mg strengths. It acts as a calcium-sensing receptor agonist to help manage high calcium levels in conditions like secondary hyperparathyroidism in chronic kidney disease patients on dialysis or parathyroid cancer. Manufactured by Strides Pharma Science Limited under ANDA209226. This information was generated using AI and is provided for informational and research purposes only.
2014-2016 NSDUH Substate Region Shapefile

This report provides a guide to the development and presentation of 2014-2016 NSDUH substate estimates. A summary of the estimation methodology is included as well as sample sizes, response rates, and population estimates. This shapefile includes geographic boundaries of the 2014-2016 NSDUH substate regions along with prevalence rates, map group values, and the upper and lower bounds found in the map legends. It can be used for analysis and data display with Geographic Information Systems (GIS) software.
Compound 530509: 2-Chlorobenzoic acid, cyclobutyl ester

Chemical compound data from PubChem database. IUPAC Name: cyclobutyl 2-chlorobenzoate. Molecular Formula: C11H11ClO2. Molecular Weight: 210.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 NSDUH Statistical Inference Report

The focus of this report is to describe the statistical inference procedures used to produce design-based estimates as presented in the 2013 detailed tables, the 2013 mental health detailed tables, the 2013 national findings report, and the 2013 mental health findings report. Thestatistical procedures and information found in this report can also be generally applied to analyses based on the public use file as well as the restricted-use file available through the data portal. This report is organized as follows: Section 2 provides background informationconcerning the 2013 NSDUH; Section 3 discusses the prevalence rates and how they were calculated, including specifics on topics such as mental illness, major depressive episode, and serious psychological distress; Section 4 briefly discusses how missing item responses of variables that are not imputed may lead to biased estimates; Section 5 discusses sampling errors and how they were calculated; Section 6 describes the degrees of freedom that were used when comparing estimates; and Section 7 discusses how the statistical significance of differences between estimates was determined. Section 8 discusses confidence interval estimation, and Section 9 describes how past year incidence of drug use was computed. Finally, Section 10 discusses the conditions under which estimates with low precision were suppressed. Appendix A contains examples that demonstrate how to conduct various statistical procedures documented within this report using SAS® and SUDAAN® Software for Statistical Analysis of Correlated Data (RTI International, 2012) along with separate examples using Stata® software.
Baclofen

Lioresal (baclofen) is a prescription injectable medication administered intrathecally (into the spinal canal) to treat severe muscle spasms and spasticity, often in conditions like multiple sclerosis or spinal cord injuries. It acts as a GABA agonist to relax muscles. Available in strengths of 0.05 mg/mL, 0.5 mg/mL, and 2 mg/mL from Amneal Pharmaceuticals LLC. This information was generated using AI and is provided for informational and research purposes only.
Oregon (OR)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Oregon overall and for substate regions within Oregon. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Compound 525237: N''-(3-bromo-phenyl)-N,N,N',N'-tetramethyl-guanidine

Chemical compound data from PubChem database. IUPAC Name: 2-(3-bromophenyl)-1,1,3,3-tetramethylguanidine. Molecular Formula: C11H16BrN3. Molecular Weight: 270.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
RxTerms

RxTerms is a drug interface terminology derived from RxNorm for prescription writing or medication history recording (e.g. in e-prescribing systems, PHRs). RxTerms is derived only from the non-proprietary content of RxNorm, which is developed and maintained by the U.S. National Library of Medicine. No fee or license is required to use the RxTerms data.  Technical documentation at https://wwwcf.nlm.nih.gov/umlslicense/rxtermApp/rxTermFileStructure.cfm
DEV DQS Use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders, by sex and race: United States.

Data on use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders in the United States, by sex and race. Data are from Health, United States. Source: Monitoring the Future, Institute for Social Research, University of Michigan, supported by National Institutes of Health, National Institute on Drug Abuse.
Search, visualize, and download these and other estimates from over 150 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.
SHIP Sudden Unexpected Infant Death Rate (SUIDs) 2009-2021

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Sudden Unexpected Infant Death Rate - This indicator shows the rate of sudden unexpected infant deaths (SUIDs) per 1,000 live births. Sudden unexpected infant deaths (SUIDs) include deaths from Sudden Infant Death Syndrome (SIDS), unknown cause, accidental suffocation and strangulation in bed. Three hundred and sixty-two babies died from SUIDs in Maryland from 2005-2009. <a href ="https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Sudden%20Unexpected%20Infant%20Death.pdf" > Link to Data Details </a>
Table 12. Alcohol Use in the Past Month among Persons Aged 12 to 20, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past month alcohol use by those aged 12 to 20 in State and substate regions.